CFG
ABBV icon

Claremont Financial Group’s AbbVie ABBV Stock Holding History

Claremont Financial Group’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$126K Buy
+727
New +$106K 0.54% 14

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Claremont Financial Group's ABBV Position: Q1 2022 in Review

Claremont Financial Group opened a new position in AbbVie (ABBV) in Q1 2022: 727 shares worth $126K. The stake represents 0.54% of the portfolio and ranks #14 among its holdings.

3,052 funds tracked by Wall St. Rank hold ABBV as of Q1 2022.

  • Claremont Financial Group held 727 shares of AbbVie worth $126K as of Q1 2022.
  • AbbVie was a new Claremont Financial Group position in Q1 2022.
  • AbbVie made up 0.54% of Claremont Financial Group's portfolio in Q1 2022, its #14 holding.
  • 3,052 funds tracked by Wall St. Rank held AbbVie as of Q1 2022.

Based on Claremont Financial Group's 13F filing for Q1 2022, filed 15 Apr 2022.